1781 results for Treatments
Refine Your Search
Early diagnosis and treatment of pre-leukemia
In the current study we propose, based on our preliminary results, that we can reliably identify pre-AML cases out of the many individuals with age re…
Development of LILRB1-based immunotherapy for multiple myeloma treatment
LILRB1 is a human immune inhibitory receptor expressed on a variety of immune cells. Based on preliminary data, we hypothesize that blocking LILRB1 si…
Delineation of the molecular heterogeneity underlying treatment failure in follicular lymphoma
A proportion of follicular lymphoma patients will experience early treatment failure and premature death. We will delineate the molecular features tha…
Chronic myelomonocytic leukemia (CMML) treatment
Blood Cancer
Acute myeloid leukemia (AML) treatment
It's important that your doctor is experienced in treating patients with acute myeloid leukemia (AML) or has access to an AML specialist.
Blood Cancer
Things to Tell Your Doctor Before Treatment
Whenever your doctor prescribes a treatment, tell him or her if: You've taken the drug before (even if you had no unusual reaction) You had an…
Types of blood cancer treatment for children and teens
Chemotherapy, stem cell transplantation, and radiation therapy are common blood cancer treatments your child may receive.
Support Resources
Development of peptide-drug conjugates for the treatment of Chronic Myelomonocytic Leukaemia (CMML)
We are aiming to bring a new treatment option to patients with chronic myelomonocytic leukemia (CMML) by utilising CCL2-drug conjugates that specifica…
Development of mutant GTPase-specific degraders for peripheral T cell lymphoma treatment
This project aims to develop targeted therapies against peripheral T cell lymphoma (PTCL), a diverse group of aggressive blood cancers with poor clini…
Cancer Treatment: How to Make Informed Choices About Cancer Treatment and Clinical Trials
Cancer Treatment: How to Make Informed Choices About Cancer Treatment and Clinical Trials Thursday, June 12, 2014 Sycamore House Re…
Heart Disease in Lymphoma Survivors
Matthew Matasar is a hematology and oncology specialist at Memorial Sloan-Kettering Cancer Center in New York City. He has a Translational Research Pr…
FDA Broadens Treatment Options for Relapsed/Refractory Multiple Myeloma
The Food and Drug Administration (FDA) has approved a new treatment, teclistamab (Tecvayli), for adults with multiple myeloma that has returned or con…
News Release
Treatment Update: Myelodysplastic Syndromes (MDS)
Topics Covered We invite you to learn more about: Myelodysplastic syndromes subtypes Current and emerging treatments Side-effects management Th…
Targeting Plek2 for the treatment of myeloproliferative neoplasms
Current therapy for MPNs remains suboptimal with ongoing risks for thrombosis. Newer drug such as JAK inhibitor has toxicity and is not curative. New …
Development of therapeutic strategy for the treatment of MDS
TP53 mutations are present in 10% of MDS cases and are associated with reduced survival and poor prognosis. However, the effect(s) of TP53 mutations o…